My watch list  


  Renzapride is a full serotonin 5-HT4 receptor agonist, partial serotonin 5-HT3 receptor antagonist.

Clinical Uses

Renzapride is currently in Phase III clinical development in the United States for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). It is also potentially effective for irritable bowel syndrome with alternating stool pattern (IBS-A). It is being developed by Alizyme of the UK.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Renzapride". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE